ClinicalTrials.gg
CompletedNCT03302065Updated Dec 2, 2024

Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Reference

A Phase 1 interventional study of Tiotropium in Healthy, sponsored by Solventum US LLC. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-02.

Sponsored by Solventum US LLC · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled May 2016, registered Oct 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to compare the absorption of four different inhalation products with the reference product in healthy volunteers.

Read the detailed description

Healthy subjects will be enrolled and will receive single doses of 4 test inhalation products and two reference inhalation products according to a five-period cross-over design. Plasma tiotropium levels will be measured pre-dose and over 48 hours post-dose.

02

Conditions studied

  • Healthy

Keywords

  • inhalation
  • anticholinergic
03

In context

Lead sponsor

Solventum US LLC is the lead sponsor of 64 studies on the registry; 2 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Volunteer
  • Willing and able to give
  • Willing to withhold all alcoholic beverages for 48 hours and all xanthine- containing foods and beverages for 24 hours prior to reporting to clinic
  • Subjects must agree to use an adequate method of from admission through 12 weeks after last administration

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of abnormalities or disease or chronic respiratory disorders
  • Any presence or history of a clinically significant allergy including any adverse reaction to study drug
  • History of drug or alcohol abuse within the past 2 years
  • Smoked tobacco within the past 6 months or have a history of more than 10- pack years (number of packs smoked per day x number of years smoked)
  • Donation or loss of greater than 400 mL of blood within the previous 3 months
  • Have received any prescription medication within 4 weeks or medication within 12 weeks of study (exception: are permitted)
  • Have received any non-prescription medication within 14 days prior to dosing (exception: paracetamol use within 2 days)
  • Upper respiratory tract infection (excluding otitis media) within 14 days of the first study day, or lower respiratory tract infection within the last 3 months
  • If female, nursing, lactating or pregnant
  • Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Test Product 1 Tiotropium

    4 inhalations

    Drug: Tiotropium

  • Experimental
    Test Product 2 Tiotropium

    4 inhalations

    Drug: Tiotropium

  • Experimental
    Test Product 3 Tiotropium

    4 inhalations

    Drug: Tiotropium

  • Active comparator
    Reference Tiotropium

    2 inhalations

    Drug: Tiotropium

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    maximum plasma concentration

    Time frame: 48 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — results will be shared through publication

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2016 to primary completion in Sep 2016, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2017
First posted
Oct 4, 2017
StartActual
May 2016
Primary completionActual
Sep 2016
CompletionActual
Jan 2017
Last update
Dec 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03302065
Lead sponsor
Solventum US LLC
Collaborators
3M
Responsible party
Sponsor
First posted
Oct 4, 2017
Start date
May 2016
Primary completion
Sep 2016
Completion
Jan 2017
Last update
Dec 2, 2024

Study contacts

Victoria Sessions, PhD
study chair · 3M

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tiotropium

Start the discussion